130308-48-4

Basic information

• Product Name: HOE 140
• Synonyms: RRP-(HYP)-G-(THI)-S-(D-TIC)-(OIC)-R;H-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH;H2N-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH;HOE 140;HOE 140 2ACOH 4H2O;D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG;D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG 2ACOH 4H2O;D-ARGINYL-[HYP3,THI5,D-TIC7,OIC8]-BRADYKININ
• CAS NO: 130308-48-4
• Molecular Formula: C59H89N19O13S
• Molecular Weight: 1304.52
• Product Categories: peptide
• Mol File: 130308-48-4.mol

Chemical Properties

• Appearance: white/powder
• Density: 1.6 g/cm³
• Refractive Index: 1.742
• Storage Temp.: −20°C
• PKA: 3.60±0.21(Predicted)
• CAS DataBase Reference: HOE 140(CAS DataBase Reference)
• NIST Chemistry Reference: HOE 140(130308-48-4)
• EPA Substance Registry System: HOE 140(130308-48-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 130308-48-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
HOE 140 is used as a bradykinin receptor antagonist for the treatment of acute attacks of hereditary angioedema in adult patients. It works by blocking the effects of bradykinin, a potent vasodilator, which helps to alleviate the symptoms of the condition.
Used in Research Applications:
HOE 140 is also used in research settings to study the role of bradykinin in various physiological processes and disease states. As a bradykinin receptor antagonist, it can help researchers understand the mechanisms underlying conditions such as inflammation, pain, and vascular permeability.

InChI:InChI=1/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38?,39-,40-,41-,42-,43?,44?,45?,46?/m0/s1

Upstream product

• 71989-33-8 Fmoc-Ser(tBu)-OH 
• 130309-33-0 N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 130309-37-4 1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid 
• 130309-35-2 Fmoc-β-(2-thienyl)-L-alanine 
• 187618-60-6 Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
• 29022-11-5 N-(fluoren-9-ylmethoxycarbonyl)glycine 
• 71989-31-6 Fmoc-Pro-OH 
• 268729-12-0 (2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 187618-60-6 N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-N^G-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine 

Relevant articles and documents

A METHOD FOR PRODUCTION OF HIGH PURITY ICATIBANT

The present invention provides a process for the manufacture of peptidomimetic drug icatibant with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a protected C-terminal fragment bound to a solid support and a protected N-terminal fragment, followed by cleavage from the support and resulting in a crude peptide of high purity, which is further purified to obtain pure icatibant in high yield. The invention further provides intermediates useful in the manufacturing process.

SYNTHESIS OF ICATIBANT

The present invention relates to the efficient solid-phase synthesis of Icatibant represented by Formula (I). The present invention relates to an efficient process for the preparation of Icatibant by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepare Icatibant. The present invention also involves the usage of inorganic salts during the coupling, wash with HOBt in DMF solution after Fmoc-deprotection step to ensure complete removal of piperidine and reactions are going for completion, and thus avoid addition/deletion sequences and also improve the process yield.

Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders

This invention relates to a method of treating a chronic fibrogenetic liver disorder and/or an acute liver disorder and/or complications associated therewith, comprising administering to a patient a therapeutically effective amount of a bradykinin antagonist. Particular complications associated with said liver disorders include portal hypertension, decompensation phenomena such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Cytolytic bradykinin antagonists

The present invention provides bradykinin antagonists effective to inhibit cancer cell growth. Also provided are methods of inhibiting lung cancer cell growth by administering a therapeutically effective amount of a dimerized bradykinin antagonist.